Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.
2.

Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.

Berman E, Arlin ZA, Gaynor J, Miller W, Gee T, Kempin SJ, Mertelsmann R, Andreeff M, Reich L, Nahmias N, et al.

Leukemia. 1989 Feb;3(2):115-21.

PMID:
2911205
3.

A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia.

Cassileth PA, Begg CB, Bennett JM, Bozdech M, Kahn SB, Weiler C, Glick JH.

Blood. 1984 Apr;63(4):843-7.

4.
5.

Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.

Linkesch W, Michlmayr G, Gerhartz H, Illinger H, König H, Düllmann J, Keilhauer R, Moldrzyk D.

Onkologie. 1989 Feb;12(1):8-10.

PMID:
2654791
6.
7.

The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia.

Woods WG, Ruymann FB, Lampkin BC, Buckley JD, Bernstein ID, Srivastava AK, Smithson WA, Benjamin DR, Feig SA, Kim TH, et al.

Cancer. 1990 Sep 15;66(6):1106-13.

9.

Daunorubicin, cytosine arabinoside and 6-thioguanine (DAT) combination chemotherapy for the treatment of acute non-lymphocytic leukemia.

Amadori S, Papa G, Meloni G, Pacilli L, Mandelli F.

Leuk Res. 1979;3(3):147-52. No abstract available.

PMID:
470431
10.
11.

Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.

Ruutu T, Almqvist A, Hallman H, Honkanen T, Järvenpää E, Järventie G, Koistinen P, Koivunen E, Lahtinen R, Lehtinen M, et al.

Leukemia. 1994 Jan;8(1):11-5.

PMID:
8289475
12.

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.

Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M.

Blood. 1996 Oct 15;88(8):2841-51.

13.

Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).

Volger WR, Weiner RS, Moore JO, Omura GA, Bartolucci AA, Stagg M.

Leukemia. 1995 Sep;9(9):1456-60.

PMID:
7544851
14.

Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.

Archimbaud E, Fiere D, Treille-Ritouet D, Adeleine P, Guyotat D, Sebban C, Vuvan H, Viala JJ.

Cancer Treat Rep. 1987 Jun;71(6):571-4.

PMID:
3555788
16.

A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.

Vogler WR, Winton EF, Gordon DS, Raney MR, Go B, Meyer L.

Blood. 1984 May;63(5):1039-45.

17.

Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: a Southwest Oncology Group study.

Bigelow CL, Kopecky K, Files JC, Head D, Lipschitz DA, Grever M, Appelbaum FR.

Am J Hematol. 1995 Apr;48(4):228-32.

PMID:
7717369
18.

Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.

Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, Fonatsch C, Haase D, Schoch C, Hossfeld D, Lengfelder E, Aul C, Heyll A, Maschmeyer G, Ludwig WD, Sauerland MC, Heinecke A.

Blood. 1999 Jun 15;93(12):4116-24.

19.

Supplemental Content

Support Center